Date | Title | Description | |
---|---|---|---|
07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download |
03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download |
12 Sep 2024 | Other relevant information | The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. | Download |
01 Aug 2024 | Other relevant information | The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. | Download |
31 Jul 2024 | Liquidity and counterparty agreements | Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |